Avalyn's AP02 Phase 1 Data Published in Respiratory Research, Supporting Lung-Targeted Nintedanib

Avalyn Pharma Inc. (AVLN) announced on September 22, 2026, that Respiratory Research has published detailed results from two Phase 1 clinical trials of AP02, a nebulized formulation of nintedanib, in healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF). The trials evaluated the lung-targeted therapy's safety, tolerability, and pharmacokinetic profile in both populations, supporting further development of the inhaled candidate for IPF. The publication follows Avalyn's prior Phase 1 readouts for AP02, part of a broader pipeline of inhaled therapies for pulmonary fibrosis. Detailed trial figures were not disclosed in the announcement. The publication provides peer-reviewed validation of the Phase 1 dataset as the company advances AP02 toward later-stage testing.